Changes in etanercept and adalimumab biosimilar prescriptions for the initial treatment of rheumatoid arthritis in France: Data from the ART-SFR Registry

Adeline Ruyssen-Witrand; Yacine Boudali; Isabelle Pane; Alain Cantagrel; Pascale Thevenot; Martin Soubrier; Jacques Morel; Eric Houvenagel; Alain Saraux; André Basch; Marie Elise Truchetet; Hubert Marotte; Emmanuelle Dernis; Pascal Claudepierre; René Marc Flipo; Jacques Eric Gottenberg; Philippe Ravaud; Xavier Mariette; Raphaele Seror

Article

Changes in etanercept and adalimumab biosimilar prescriptions for the initial treatment of rheumatoid arthritis in France: Data from the ART-SFR Registry

Joint Bone Spine

DOI: 10.1016/j.jbspin.2021.105310

2Citations

7Readers

Get full text

Author supplied keywords

Cite

CITATION STYLE

APA

Ruyssen-Witrand, A., Boudali, Y., Pane, I., Cantagrel, A., Thevenot, P., Soubrier, M., … Seror, R. (2022, May 1). Changes in etanercept and adalimumab biosimilar prescriptions for the initial treatment of rheumatoid arthritis in France: Data from the ART-SFR Registry. Joint Bone Spine. Elsevier Masson s.r.l. https://doi.org/10.1016/j.jbspin.2021.105310

Changes in etanercept and adalimumab biosimilar prescriptions for the initial treatment of rheumatoid arthritis in France: Data from the ART-SFR Registry

Author supplied keywords

Cite

Register to see more suggestions